The 5 most recent market catalysts affecting $VANI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Neutral
Impact 65
Vivani Medical Announces Private Placement Equity Financing
Vivani Medical secured $5.1 million through a private placement, with the shares purchased by the Chairman and a board member. This insider participation is a strong signal of conf…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 75
Vivani Medical Reports Positive Phase 1 Results for NPM-139 Semaglutide Implant
Vivani Medical reported positive Phase 1 results for its NPM-139 semaglutide implant, demonstrating strong safety and tolerability. This is significant because the implant aims to …
Nov 12, 2026
Corporate Catalyst
Neutral
Impact 75
Vivani Medical Reports Third Quarter 2026 Financial Results
Vivani Medical's Q3 2026 financial results showed a modest increase in R&D spending, primarily due to clinical trial costs, and a stable cash balance of $15.5 million. While the fi…
Nov 12, 2026
Corporate Catalyst
Bullish
Impact 75
Vivani Medical Announces Positive Top-Line Results from SLIM-1 Phase 1 Trial
Vivani Medical reported positive top-line results from its SLIM-1 Phase 1 clinical trial for NPM-139, a miniature, subdermal semaglutide implant designed for continuous drug delive…
Oct 31, 2026
Corporate Catalyst
Neutral
Impact 65
Vivani Medical Updates Status of Planned Cortigent Merger
Vivani Medical provided an update on its planned merger with Cortigent, indicating that the transaction is still awaiting final regulatory approval. This pushes back the previously…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.